Journal of Medicinal Chemistry · 2007 · 167 citations · 22 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyAngiogenesisAngiogenesis In CancerOncology PharmacologyPharmacokinetics Of Anticancer DrugsTyrosine Kinase InhibitorsCorneal AngiogenesisProliferation AssaysVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor InhibitorsVascular Endothelial Growth Factor ReceptorsVegf Pathway InhibitionVegfr Inhibitors
Inhibition of the VEGF signaling pathway has become a valuable approach in the treatment of cancers. Guided by X-ray crystallography and molecular modeling, a series of 2-aminobenzimidazoles and 2-aminobenzoxazoles were identified as potent inhibitors of VEGFR-2 (KDR) in both enzymatic and HUVEC cellular proliferation assays. In this report we describe the synthesis and structure-activity relationship of a series of 2-aminobenzimidazoles and benzoxazoles, culminating in the identification of benzoxazole 22 as a potent and selective VEGFR-2 inhibitor displaying a good pharmacokinetic profile. Compound 22 demonstrated efficacy in both the murine matrigel model for vascular permeability (79% inhibition observed at 100 mg/kg) and the rat corneal angiogenesis model (ED(50) = 16.3 mg/kg).
22
Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text
Medicine, Oncology, Pharmacology +17
Role of angiogenesis in tumor growth and metastasis
J Folkman · Seminars in Oncology · 2002 · 2.4K citations
Medicine, Cancer Biology, Oncology +12
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Thomas H. Schindler, William G. Bornmann, Patricia Pellicena et al. · Science · 2000 · 1.8K citations